Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits

British Journal of Pharmacology

Volumn 118, Issue 2, 1996, Pages 215-219

  Soma, M R ^a   Donetti, E ^a   Seregni, R ^a   Barberi, L ^a   Fumagalli, R ^a   Paoletti, R ^a   Catapano, A L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Animal model; Atherosclerosis; Calcium antagonists; Fatty lesion; Lacidipine; Proliferative lesion; Smooth muscle cell proliferation

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACIDIPINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029874968     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15389.x     Document Type: Article

References (34)

1. BERNINI, F. & ALLORIO, M. (1988). Calcium antagonists and low density lipoprotein receptors. Ann. N.Y. Acad. Sci., 522, 390-398.
2. BERNINI, F., BELLOSTA, S., DIDONI, G. & FUMAGALLI, R. (1991). Calcium antagonists and cholesteryl ester metabolism in macrophages. J. Cardiovasc. Pharmacol., 18 (suppl. 10), S42-S45.
3. BERNINI, F., CATAPANO, A.L., CORSINI, A. FUMAGALLI, R. & PAOLETTI, R. (1989). Effects of calcium antagonists on lipids and atherosclerosis. Am. J. Cardiol., 64, 1291-1341.
4. BERNINI, F., CORSINI, A., MAZZOTTI, M., BELLOSTA, S., SOMA, M.R. & PAOLETTI, R. (1993a). Lacidipine and atherosclerosis. In Calcium Antagonists: Pharmacology and Clinical Research. ed. Vanhoutte, P.M., Paoletti, R., Govoni, S. & Godfraind, T. pp. 157-164. Kluwer Academic.
5. BERNINI, F., CORSINI, A., RAITERI, M., SOMA, M.R. & PAOLETTI, R. (1993b). Effects of lacidipine on experimental models of atherosclerosis. J. Hypertens., 11 (Suppl.3), S61-S66.
6. CAREW, T.E., SCHWENKE, D.C. & STEINBERG, D. (1987). Anti-atherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U.S.A., 84, 7725-7729.
7. CATAPANO, A.L., MAGGI, F.M. & CICERANO, V. (1988). The antiatherosclerotic effect of anipamil in cholesterol-fed rabbits. Ann. N.Y. Acad. Sci., 522, 519-521.
8. CORSINI, A., QUARATO, P., RAITERI, M., PAUBERT-BRAQUET, M., NGUYEN, G., PIQUOT, S., CORSINI, A., QUARATO, P., RAITERI, M., PAUBERT-BRAUQET, M., NGUYEN, G., PIQUOT, S., BOURGAIN, R.H., FUMAGALI, R. & PAOLETTI, R. (1993). Effect of nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol. Res., 27, 299-307.
9. CORSINI, A., RAITERI, M., DIMITRI, V., DONETTI, E., SOMA, M.R., BERNINI, F., CORSINI, A., RAITERI, M., DIMITRI, V., DONETTI, E., SOMA, M.R., BERNINI, F., FUMAGALLI, R. & PAOLETTI, R. (1994). Vascular smooth muscle and atherosclerosis: role of isoprenoids and calcium antagonists. J. Vasc. Med. Biol., 5, 111-119.
10. DAUGHERTY, A., RATERI, D.L. & SCHONFELD, S.B. (1987). Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br. J. Pharmacol., 91, 113-118.
11. DAUGHERTY, A., ZWEIFEL, B.S. & SCHONFELD, G. (1989). Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br. J. Pharmacol., 98, 612-618.
12. ERIKSON, U., NILSSON, S. & STENPORT, G. (1988). Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Am. J. Cardiol., 62, 44B-47B.
13. HENRY, P.D. (1990). Calcium channel blockers and atherosclerosis. J. Cardiovasc. Pharmacol., 16, S12-S15.
14. JACKSON, C.L. & SCHWARTZ, S.M. (1992). Pharmacology of smooth muscle cell replication. Hypertension, 20, 713-736.
15. KEOGH, A.M. & SCHROEDER, S. (1990). A review of calcium antagonists and atherosclerosis. J. Cardiovasc. Pharmacol., 16, S28-S35.
16. KITA, T., NAGANO, Y., YOKODE, M., ISHII, K., KUME, N., OOSHIMA, A., KITA, T., NAGANO, Y., YOKODE, M., ISHII, K., OOSHIMA, A., YOSHIDA, H. & KAWAI, C. (1987). Probucol prevents the progression of atherosclerosis in Watanabe heritable hperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. U.S.A., 84, 5928-5931.
17. KUNJARA-NA-AYUDHYA, R., THOMSON, A.B. & KAPPAGODA, C.T. (1994). Effect of Isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits. Cardiovasc. Res., 28, 1089-1095. (Abstract).
18. LICHTLEN, P.R., NELLESSEN, U., RAFFLENBLEU, W. & HECKER, H. (1987). International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Cardiovasc. Drugs Ther., 1, 71-79.
19. LICHTOR, T., DAVIS, H.R., VESSELINOVITCH, D. & MULLAN, S. (1989). Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey. Appl. Pathol., 7, 8-18.
20. NAYLER, W.G. (1992). Calcium channels and their involvement in cardioavascular disease. Biochem. Pharmacol., 43, 39-46.
21. NAYLER, W.G. (1993). Phamacological aspects of calcium antagonism. Short term and long term benefits. Drugs, 46, 40-47. (Abstract).
22. NOMOTO, A., MUTOH, S., HAGIHARA, H. & YAMAGUCHI, I. (1988). Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist. nilvadipine. Atherosclerosis, 72, 213-219.
23. PARMLEY, W.W. (1987). Calcium channel blockers and atherogenesis. Am. J. Med., 82, 3-8.
24. POPMA, J.J., CALIFF, R.M. & TOPOL, E.J. (1991). Clinical trials of restenosis after coronary angioplasty. Circulation, 84, 1426-1436.
25. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
26. ++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. Arteriosclerosis, 8, 46-56.
27. SOMA, M.R., BERNINI, F., CORSINI, A. & PAOLETTI, R. (1994). Calcium antagonists in atherosclerosis: focus on lacidipine. Res. Clin. Forums, 16, 47-51.
28. SOMA, M.R., DONETTI, E., PAROLINI, C., MAZZINI, G., FERRARI, C., FUMAGALLI, R., SOMA, M.R., DONETTI, E., PAROLINI, C., MAZZINI, G., FERRARI, C., FUMAGALLI, R. & PAOLETTI, R. (1993). HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscl. Thromb., 13, 571-578.
29. SOMA, M.R., DONETTI, E., PAROLINI, C., SIRTORI, C.R., FUMAGALLI, R. & FRANCESCHINI, G. (1995a). Recombinant apolipoprotein A-IMilano dimer inhibits carotid intima thickening induced by perivascular manipulation in rabbits. Circ. Res., 76, 405-411.
30. SOMA, M.R., PAROLINI, C., DONETTI, E., FUMAGALLI, R. & PAOLETTI, R. (1995b). Inhibition of isoprenoid biosynthesis and arterial smooth muscle cell proliferation. J. Cardiovasc. Pharmacol., 25 suppl. 4, S20-S24.
31. STEIN, O. & STEIN, Y. (1987). Effect of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages. Arteriosclerosis, 7, 578-584.
32. WATERS, D. & LESPERANCE, J. (1994). Calcium Channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am. Heart J., 128, 1309-1316. (Abstract)
33. WATERS, D., LESPÉRANCE, J., THEROUX, P., FRANCETICH, M., REITMAN, M. & HAVEL, R.J. (1990). Prevention of progression of minimal coronary lesions with a calcium channel blocker. J. Am. Coll. Cardiol., 15, 116A.
34. WEINSTEIN, D.B. & HEIDER, J.G. (1989). Antiatherogenic properties of calcium antagonists: state of the art. Am. J. Med., 86 (Suppl. 4A), 27-32.